HK Stock Market Move | JUNSHI BIO (01877) rose by over 4%. Clinical trial application for JS212 for the treatment of late-stage solid tumors has been approved by the FDA.

JUNSHI BIO (01877) rose more than 4%, as of the time of writing, it has risen by 4.33% to 25 Hong Kong dollars, with a trading volume of 34.83 million Hong Kong dollars. In terms of news, on December 14th, JUNSHI BIO announced that the company had received notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for the EGFR/HER3 bispecific antibody conjugate drug (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA. In January 2025, the clinical trial application for JS212 was accepted by the National Medical Products Administration (NMPA) and received approval from the NMPA in March 2025. As of the date of this announcement, JS212 is conducting an open-label, dose-escalation, and dose-expansion Phase I/II clinical trial in mainland China to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212 in patients with advanced solid tumors. In addition, the clinical trial application for the combination therapy of JS212 in multiple cohorts was approved by the NMPA in November 2025 and is scheduled to start relevant clinical studies soon.